A Randomised, Stratified, Open Label, Phase II Pilot Study on the Safety of a Daily, Intermittent, or Weekly Administration of 1, 3 or 10mg/kg of AmBisome in Antifungal Primary Prophylaxis of High-Risk Patients With Acute Myeloid Leukaemia
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Amphotericin B liposomal (Primary)
- Indications Mycoses
- Focus Adverse reactions
- 18 Dec 2013 New trial record